Provider-Administered Oncology Drug Policies - Blue Advantage

Blue Advantage provider-administered oncology drug policies are based on the most current medical research available at the time of the policy development. We list final and draft provider-administered oncology policies as well as supportive drug policies. The draft policies are available for physician comment for 45-days from the posting date found on the document. We encourage practicing physicians to provide input.

Policies are written to cover a given therapy for the majority of people. Each individual's unique clinical circumstances may be considered in light of current scientific literature. Provider-administered oncology drug policies are based on constantly changing medical science and Blue Cross reserves the right to review and update our policies as necessary.

Draft Blue Advantage  Provider-Administered Oncology Drug Policies